Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Pfizer's blood cancer treatment achieved its primary endpoint in a late-stage clinical trial

Pfizer's blood cancer treatment achieved its primary endpoint in a late-stage clinical trial

格隆汇格隆汇2026/04/29 13:30
Show original
Glonghui, April 29 — Pfizer announced on Wednesday that its drug Elrexfio achieved its primary endpoint in a late-stage clinical trial involving blood cancer patients who had previously received at least one line of therapy. Elrexfio has already received accelerated approval from the US Food and Drug Administration (FDA) for the treatment of multiple myeloma patients who have undergone at least four prior lines of therapy.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The Nasdaq 100 rebalancing will take effect before the U.S. stock market opens on Monday, SpaceX (SPCX.US) weight significantly rises to 2.82%.

The Nasdaq 100 Index quarterly rebalancing will take effect before the US stock market opens on September 21 (Monday). The main change is that SpaceX (SPCX.US) will see its index weighting significantly increase from about 1.28% to 2.82%.

智通财经2026/09/21 02:36

South Korea's exports in the first 20 days of September continued strong momentum, with chip exports soaring by 259%, remaining a key driver of growth.

Early September exports from South Korea help maintain strong momentum in the chip boom.

智通财经2026/09/21 01:56